Literature DB >> 15168383

Defective regulation of iron transporters leading to iron excess in the polymorphonuclear leukocytes of patients on maintenance hemodialysis.

Yoshinaga Otaki1, Takeshi Nakanishi, Yukiko Hasuike, Rintarou Moriguchi, Masayoshi Nanami, Yasue Hama, Masaaki Izumi, Yoshihiro Takamitsu.   

Abstract

BACKGROUND: Although hemodialysis (HD) patients are suspected of having defectively regulated iron metabolism, intracellular iron status has never been investigated thoroughly. To clarify the iron metabolism of HD patients, proteins involved in iron import (transferrin receptor [TfR]), as well as export (ferroportin 1), were investigated in polymorphonuclear leukocytes (PMNLs). Relations between iron status and several PMNL functions also were tested.
METHODS: Seventeen HD patients and 17 controls were recruited. Relative quantitative polymerase chain reaction was used to measure ferroportin 1 and TfR messenger RNA (mRNA), and ferroportin 1 and TfR expression were semiquantified by means of Western blot analysis or immunohistochemistry. PMNL functions also were examined.
RESULTS: Serum iron levels were significantly lower in HD patients than controls, and serum ferritin levels, as well as PMNL ferritin and iron content, were elevated in HD patients. Ferroportin 1 mRNA levels were substantially lower in PMNLs from HD patients, whereas TfR mRNA levels were higher. Western blot analysis and immunohistochemistry confirmed that expression of the corresponding proteins paralleled those of the mRNAs. PMNL phagocytic and bactericidal activity did not differ between HD patients and controls. Chemotactic peptide f-Met-Leu-Phe-stimulated degranulation activity of lactoferrin (Lf) was decreased significantly in HD patients, whereas those of myeloperoxidase and elastase were accelerated. Lf release correlated negatively with intracellular ferritin level.
CONCLUSION: We show for the first time that increased iron levels in PMNLs of HD patients were associated with downregulation of ferroportin 1 and upregulation of TfR, which might be linked to hypercytokinemia.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15168383     DOI: 10.1053/j.ajkd.2004.02.016

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  10 in total

1.  Serum ferritin predicts prognosis in hemodialysis patients: the Nishinomiya study.

Authors:  Yukiko Hasuike; Hiroshi Nonoguchi; Masanori Tokuyama; Mai Ohue; Takanori Nagai; Mana Yahiro; Masayoshi Nanami; Yoshinaga Otaki; Takeshi Nakanishi
Journal:  Clin Exp Nephrol       Date:  2010-05-14       Impact factor: 2.801

2.  Erythropoietin stimulation decreases hepcidin expression through hematopoietic activity on bone marrow cells in mice.

Authors:  Yusuke Sasaki; Mariko Noguchi-Sasaki; Hideyuki Yasuno; Keigo Yorozu; Yasushi Shimonaka
Journal:  Int J Hematol       Date:  2012-11-16       Impact factor: 2.490

Review 3.  Secondary Immunodeficiency Related to Kidney Disease (SIDKD)-Definition, Unmet Need, and Mechanisms.

Authors:  Stefanie Steiger; Jan Rossaint; Alexander Zarbock; Hans-Joachim Anders
Journal:  J Am Soc Nephrol       Date:  2021-12-14       Impact factor: 10.121

4.  Reduction of a marker of oxidative stress with enhancement of iron utilization by erythropoiesis activation following epoetin beta pegol administration in iron-loaded db/db mice.

Authors:  Mariko Noguchi-Sasaki; Yusuke Sasaki; Yukari Matsuo-Tezuka; Hideyuki Yasuno; Mitsue Kurasawa; Keigo Yorozu; Yasushi Shimonaka
Journal:  Int J Hematol       Date:  2016-01-06       Impact factor: 2.490

5.  Epoetin beta pegol (C.E.R.A.) promotes utilization of iron for erythropoiesis through intensive suppression of serum hepcidin levels in mice.

Authors:  Yusuke Sasaki; Mariko Noguchi-Sasaki; Yukari Matsuo-Tezuka; Yuki Matsumoto-Omori; Mitsue Kurasawa; Keigo Yorozu; Yasushi Shimonaka
Journal:  Int J Hematol       Date:  2014-03-13       Impact factor: 2.490

6.  The mitochondrial protein frataxin is downregulated in hemodialysis patients.

Authors:  Yukiko Hasuike; Takanori Nagai; Soshi Yorifuji; Saiko Tanaka; Ayako Matsumoto; Mana Yahiro; Shoji Kaibe; Aritoshi Kida; Masanori Tokuyama; Yasuyuki Nagasawa; Yoshinaga Otaki; Takahiro Kuragano; Takeshi Nakanishi
Journal:  Clin Exp Nephrol       Date:  2012-11-23       Impact factor: 2.801

Review 7.  Should we reconsider iron administration based on prevailing ferritin and hepcidin concentrations?

Authors:  Takeshi Nakanishi; Takahiro Kuragano; Shoji Kaibe; Yasuyuki Nagasawa; Yukiko Hasuike
Journal:  Clin Exp Nephrol       Date:  2012-09-29       Impact factor: 2.801

8.  Lactoferrin is a survival factor for neutrophils in rheumatoid synovial fluid.

Authors:  S H Wong; N Francis; H Chahal; K Raza; M Salmon; D Scheel-Toellner; J M Lord
Journal:  Rheumatology (Oxford)       Date:  2008-11-23       Impact factor: 7.580

9.  Erythropoiesis-independent effects of iron in chronic kidney disease.

Authors:  Edwin Patino; Oleh Akchurin
Journal:  Pediatr Nephrol       Date:  2021-07-09       Impact factor: 3.651

Review 10.  A Bioinformatics-Assisted Review on Iron Metabolism and Immune System to Identify Potential Biomarkers of Exercise Stress-Induced Immunosuppression.

Authors:  Diego A Bonilla; Yurany Moreno; Jorge L Petro; Diego A Forero; Salvador Vargas-Molina; Adrián Odriozola-Martínez; Carlos A Orozco; Jeffrey R Stout; Eric S Rawson; Richard B Kreider
Journal:  Biomedicines       Date:  2022-03-21
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.